Milada Šírová
YOU?
Author Swipe
View article: Temporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion
Temporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion Open
Background Interleukin-2 (IL-2) immunotherapy can induce durable tumor remissions, but its clinical performance has been limited by significant drawbacks such as short serum half-life and high toxicity. Administration of IL-2 in complex wi…
View article: Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v
Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v Open
Background SOT201 and its murine surrogate mSOT201 are novel cis-acting immunocytokines consisting of a humanized/murinized/, Fc-silenced anti-programmed cell death protein 1 (PD-1) monoclonal antibody (mAb) fused to an attenuated human in…
View article: Overcoming P-glycoprotein-mediated multidrug resistance in cancer cells through micelle-forming PHPMA-b-PPO diblock copolymers for doxorubicin delivery
Overcoming P-glycoprotein-mediated multidrug resistance in cancer cells through micelle-forming PHPMA-b-PPO diblock copolymers for doxorubicin delivery Open
Multidrug resistance (MDR) represents one of the major concerns in cancer therapy as it may cause reduced efficacy of chemotherapeutic drugs due to the overexpression of ABC transporters, particularly P-glycoprotein (P-gp). This study expl…
View article: 1087 SOT201 is a novel cis-acting immunocytokine targeting IL-15Rβγ to reinvigorate PD-1<sup>+</sup>tumor infiltrating lymphocytes and potentiate anti-tumor efficacy
1087 SOT201 is a novel cis-acting immunocytokine targeting IL-15Rβγ to reinvigorate PD-1<sup>+</sup>tumor infiltrating lymphocytes and potentiate anti-tumor efficacy Open
Background SOT201 is a novel cis-acting immunocytokine consisting of a humanized, Fc-silenced monoclonal antibody against PD-1 fused to a covalent RLI-15 complex of a human attenuated IL-15 mutein linked to the high-affinity binding site o…
View article: Evaluation of linear versus star-like polymer anti-cancer nanomedicines in mouse models
Evaluation of linear versus star-like polymer anti-cancer nanomedicines in mouse models Open
Nanomedicines are considered next generation therapeutics with advanced therapeutic properties and reduced side effects. Herein, we introduce tailored linear and star-like water-soluble nanosystems as stimuli-sensitive nanomedicines for th…
View article: SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity
SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity Open
SOT101 is a superagonist fusion protein of interleukin (IL)-15 and the IL-15 receptor α (IL-15Rα) sushi+ domain, representing a promising clinical candidate for the treatment of cancer. SOT101 among other immune cells specifically stimulat…
View article: HPMA-Based Copolymers Carrying STAT3 Inhibitor Cucurbitacin-D as Stimulus-Sensitive Nanomedicines for Oncotherapy
HPMA-Based Copolymers Carrying STAT3 Inhibitor Cucurbitacin-D as Stimulus-Sensitive Nanomedicines for Oncotherapy Open
The study describes the synthesis, physicochemical properties, and biological evaluation of polymer therapeutics based on N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers intended for a tumor-targeted immuno-oncotherapy. Water-soluble l…
View article: Micelle-Forming Block Copolymers Tailored for Inhibition of P-gp-Mediated Multidrug Resistance: Structure to Activity Relationship
Micelle-Forming Block Copolymers Tailored for Inhibition of P-gp-Mediated Multidrug Resistance: Structure to Activity Relationship Open
Multidrug resistance (MDR) is often caused by the overexpression of efflux pumps, such as ABC transporters, in particular, P-glycoprotein (P-gp). Here, we investigate the di- and tri- block amphiphilic polymer systems based on polypropylen…
View article: Polymer donors of nitric oxide improve the treatment of experimental solid tumours with nanosized polymer therapeutics
Polymer donors of nitric oxide improve the treatment of experimental solid tumours with nanosized polymer therapeutics Open
Polymer carriers based on N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers with incorporated organic nitrates as nitric oxide (NO) donors were designed with the aim to localise NO generation in solid tumours, thus highly increasing the …
View article: Star Polymer-Drug Conjugates with pH-Controlled Drug Release and Carrier Degradation
Star Polymer-Drug Conjugates with pH-Controlled Drug Release and Carrier Degradation Open
In this study, we describe the design, synthesis, and physicochemical and preliminary biological characteristics of new biodegradable, high-molecular-weight (HMW) drug delivery systems with star-like architectures bearing the cytotoxic dru…
View article: HPMA Copolymer-Based Polymer Conjugates for the Delivery and Controlled Release of Retinoids
HPMA Copolymer-Based Polymer Conjugates for the Delivery and Controlled Release of Retinoids Open
In this paper, we describe the synthesis, physicochemical characterization, drug release kinetics and preliminary biological evaluation of several N-(2-hydroxypropyl)methacrylamide (HPMA)-based polymer-retinoid conjugates designed for soli…